Endocrine Abstracts

Introduction: Weight gain and its associated adverse health consequences have become a significant aspect of the life experience of many people with schizophrenia and other severe enduring mental illnesses (SMIs). Glucagon-like peptide -1(GLP-1) receptor agonists could be of substantial value in addressing this unmet need. We aimed to determine whether semaglutide treatment is feasible and acceptable to individuals in an inpatient setting and successful in facilitating weight ...